About RNACure
Founded in 2019, RNACure is dedicated to building foundational capabilities for mRNA therapeutics. We focus on mRNA molecular engineering, delivery systems, and immune modulation as three core pillars—emphasizing verifiability, reusability, and continuous iteration.
We view CMC as an integral part of the platform: an engineering-driven approach to reproducible process pathways and robust quality strategies, enhancing scalability and consistency across programs.
Through real regulatory submissions and clinical advancement, we continuously embed regulatory requirements upstream into our technology stack, ensuring the platform is validated—and evolves—through real-world execution.
Core Mission
RNACure is committed to turning mRNA, a next-generation biopharmaceutical platform, into a trusted foundation for modern healthcare. By addressing major infectious disease threats and critical unmet medical needs, we deliver solutions that originate in China and are built for global impact.
We invest deeply in the core capabilities of mRNA innovation, from molecular design and delivery systems to precise control of immune outcomes. Through real programs, we translate breakthroughs beyond publications and proof of concept into manufacturable processes, dependable quality, and sustained supply, advancing what is possible for human health and longevity.
Our Vision
In Chinese mythology, the blue magpie serves as a trusted messenger—carrying life-changing news across distance and uncertainty. RNACure brings that spirit into modern medicine: we deliver RNA innovations from the lab to the people who need them, reliably and responsibly. By pioneering scalable vaccines and immunotherapies, we aim to reduce the burden of disease worldwide and expand what is possible for human health.
Our Story
CDE clinical trial authorization, advancing next-generation mRNA vaccine into clinical stage.
CDE clinical trial authorization, enabling parallel domestic clinical development.
FDA clinical trial authorization, advancing global clinical development.
CDE clinical trial authorization, advancing next-generation mRNA vaccine into clinical stage.
CDE clinical trial authorization, enabling parallel domestic clinical development.
FDA clinical trial authorization, advancing global clinical development.
A landmark regulatory and clinical translation milestone.
A landmark regulatory and clinical translation milestone.
Reached a key regulatory milestone with a clear clinical advancement path.
Reached a key regulatory milestone with a clear clinical advancement path.
Enhanced platform capability and engineering translation through industry–academia collaboration.
Enhanced platform capability and engineering translation through industry–academia collaboration.
Built organizational and platform capacity for sustained iteration and translation.
Accelerated R&D and validation with vaccines as a key direction.
Built organizational and platform capacity for sustained iteration and translation.
Accelerated R&D and validation with vaccines as a key direction.
Company operations started; platform R&D entered a systematic execution phase.
Validated production scale capability.
Company operations started; platform R&D entered a systematic execution phase.
Validated production scale capability.
Scaled synthesis of Cap1 analogs; established in-house raw material capability.
Scaled synthesis of Cap1 analogs; established in-house raw material capability.
Launched foundational platform planning and systematic R&D.
Launched foundational platform planning and systematic R&D.
Our Values
Our Honors
R&D and Pilot-Scale Capabilities
Located in Shanghai Bay Valley Science and Technology Park, the Wangu R&D Center spans ~3,000 m². The team covers clinical medicine, biochemistry, biophysics, structural biology, organic chemistry, medicinal chemistry, and public health—focusing on innovation and platform capability accumulation for mRNA medicines.
RNACure has established an ~10,000 m² GMP manufacturing base at Guosheng Botai · Baoshan Pharma Valley (Luodian Town, Baoshan, Shanghai), complemented by the ~5,000 m² Songnan R&D center, forming a "south R&D, north manufacturing" layout. The facility is planned to support up to 50 million doses of clinical-stage mRNA drug production capacity, enabling end-to-end delivery from process development to clinical supply for infectious disease vaccines, oncology immunotherapies, and other pipelines.
We view “R&D–pilot scale–submission–clinical validation” as a continuous engineering system. Through standardized workflows, traceable data, and consistent quality strategies, platform capabilities can be verified, replicated, and continuously evolved.
